Skip to main content
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
letter
. 2020 Sep 1;64(4):656–659. doi: 10.1007/s11427-020-1791-3

Structure of SARS-CoV-2 main protease in the apo state

Xuelan Zhou 1,#, Fanglin Zhong 2,3,#, Cheng Lin 4,5, Xiaohui Hu 1, Yan Zhang 6, Bing Xiong 7, Xiushan Yin 8,9, Jinheng Fu 10, Wei He 2, Jingjing Duan 11, Yang Fu 12, Huan Zhou 13, Peter J McCormick 14, Qisheng Wang 13,, Jian Li 2,3,, Jin Zhang 1,
PMCID: PMC7471536  PMID: 32880863

The content is available as a PDF (2.4 MB).

Electronic supplementary material

11427_2020_1791_MOESM1_ESM.docx (21.5KB, docx)

Supplementary material, approximately 24 KB.

Acknowledgements

This work was supported by the Thousand Young Talents Program of China, the National Natural Science Foundation of China (31770795 and 81974514), the Jiangxi Province Natural Science Foundation (20181ACB20014), the Open Project of Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Ministry of Education (XN201904), Gannan Medical University (QD201910), Jiangxi “Double Thousand Plan”, the Foreign Talent project of Jiangxi Province, and Ganzhou COVID-19 Emergency Research Project.

Footnotes

Compliance and ethics

The author(s) declare that they have no conflict of interest.

Contributed equally to this work

Contributor Information

Qisheng Wang, Email: wangqisheng@zjlab.org.cn.

Jian Li, Email: rmsl_2040@163.com.

Jin Zhang, Email: zhangxiaokong@hotmail.com.

References

  1. Dai W, Zhang B, Jiang XM, Su H, Li J, Zhao Y, Xie X, Jin Z, Peng J, Liu F, et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. 2020;368:1331–1335. doi: 10.1126/science.abb4489. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Hilgenfeld R. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J. 2014;281:4085–4096. doi: 10.1111/febs.12936. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582:289–293. doi: 10.1038/s41586-020-2223-y. [DOI] [PubMed] [Google Scholar]
  4. Jin Z, Zhao Y, Sun Y, Zhang B, Wang H, Wu Y, Zhu Y, Zhu C, Hu T, Du X, et al. Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Nat Struct Mol Biol. 2020;27:529–532. doi: 10.1038/s41594-020-0440-6. [DOI] [PubMed] [Google Scholar]
  5. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–574. doi: 10.1016/S0140-6736(20)30251-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Yang H, Yang M, Ding Y, Liu Y, Lou Z, Zhou Z, Sun L, Mo L, Ye S, Pang H, et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc Natl Acad Sci USA. 2003;100:13190–13195. doi: 10.1073/pnas.1835675100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Zumla A, Chan JFW, Azhar EI, Hui DSC, Yuen KY. Coronaviruses—Drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15:327–347. doi: 10.1038/nrd.2015.37. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

11427_2020_1791_MOESM1_ESM.docx (21.5KB, docx)

Supplementary material, approximately 24 KB.


Articles from Science China. Life Sciences are provided here courtesy of Nature Publishing Group

RESOURCES